CBER chief forecasts better global regulatory convergence around cell and gene therapies

Peter Marks, who’s responsible for the FDA’s oversight of cell and gene therapies, expects regulators around the world will be better at collaborating on gene …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SCHOTT Pharma reports good start into fiscal year 2024 – Biotech Investments

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Quarterly / Interim Statement/Quarter Results SCHOTT Pharma reports good start into fiscal year 2024 29.02.2024

March 1, 2024

The VIX analysis and why a government shutdown will rock markets like UVIX stock & VIXY stock

September 16, 2023

Study reveals altered neural signature in patients with depression

As parents, teachers and pet owners can attest, rewards play a huge role in shaping behaviors in humans and animals.

July 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.